A Phase 3 interventional study of Ranibizumab and Laser therapy in Retinopathy of Prematurity, sponsored by Novartis Pharmaceuticals. Completed at 86 sites in 26 countries. Per ClinicalTrials.gov, last updated 2018-11-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP).
The study consisted of a screening period (screening and randomization could occur up to 3 days before the administration of the first investigational treatment), followed by a treatment and follow-up period (Day 1 to Day 169).
169 studies on the registry are indexed under Retinopathy of Prematurity; 27 are open to participants now.
This study's enrollment of 224 is above the median of 82 across 102 interventional studies indexed under Retinopathy of Prematurity.
Browse Retinopathy of Prematurity studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Drug: Ranibizumab
1 intravitreal injection in both eyes on Day 1 (Baseline), with up to 2 re-treatments allowed for each eye if required
Drug: Ranibizumab
Laser treatment to each eye on Day 1 (Baseline), with supplementary treatments allowed
Procedure: Laser therapy
Administered as an intravitreal injection
Transpupillary diode or frequency-doubled yttrium aluminum garnet (YAG) laser ablative therapy, following anesthesia or sedation
Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24
To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome. Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.
Time frame: Week 24
Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24
Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment. Only descriptive analysis done.
Time frame: Week 24
Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit
An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye. Only descriptive analysis done.
Time frame: Day 1 (after initiation of study treatment) up to study exit (Day 169)
Percentage of Participants Having Recurrent ROP and Receiving Any Post-baseline Intervention at or Before Week 24
Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group). Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula. Zone II extends centrifugally from the edge of zone I to the nasal ora serrata. Only descriptive analysis done.
Time frame: Week 24
Percent of Participants With Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.
Time frame: Week 24
Mean Change in Ranibizumab Concentration in Pharmacokinetic Serum Samples Over Time at Day 1, Day 15 and Day 29
Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29. Only descriptive analysis done.
Time frame: Day 1 (Baseline), Day 15 and Day 29
Mean Change in Vascular Endothelial Growth Factor (VEGF) Levels Over Time at Day 1, Day 15 and Day 29
Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29. Only descriptive analysis done.
Time frame: Day 1 (Baseline), Day 15 and Day 29
Total Number of Ranibizumab Injections Received at Week 24
Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline). Only descriptive analysis done.
Time frame: Week 24
Percent of Participants With Non-Ocular Adverse Events by Primary System Organ (SOCs) at Week 24
Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.
Time frame: Week 24
Mean Change From Baseline in Vital Signs (Body Length, Head Circumference and Knee to Heel Length) at Day 85 and Day 169
Body Length, Head Circumference and Knee to Heel Length were assessed. Only descriptive analysis done.
Time frame: Baseline, Day 85, Day 169
Mean Change From Baseline in Vital Signs (Weight) at Day 85 and Day 169
Body weight was measured. Only descriptive analysis done.
Time frame: Baseline, Day 85, Day 169
Mean Change From Baseline in Vital Signs (Sitting Blood Pressure) at Day 85 and Day 169
Blood Pressure measurements were not required by the protocol. Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used. Only descriptive analysis done.
Time frame: Baseline, Day 85, Day 169
This study was conducted in 87 sites: Austria(2), Belgium(2), Croatia(2), Czech Republic(3), Denmark(1), Egypt(1), Estonia(1), France(2), Germany(2), Greece(3), Hungary(2), India(6), Italy(4), Japan(17), Lithuania(1), Malaysia(2), Mexico(1), Poland(2), Romania(3), Russia(5), Saudi Arabia(1), Slovakia(1), Taiwan(2), Turkey(6), UK(3) and USA(12).
| Milestone | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Started | 74 | 77 | 74 |
| Safety set | 73 | 76 | 69 |
| Vegf set | 19 | 26 | 51 |
| Pk set | 49 | 46 | 0 |
| Completed | 73 | 76 | 69 |
| Not completed | 1 | 1 | 5 |
| Withdrew: Subj/guardian decision | 0 | 0 | 2 |
| Withdrew: Physician decision | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Started | 73 | 76 | 69 |
| Completed | 66 | 71 | 64 |
| Not completed | 7 | 5 | 5 |
| Withdrew: Adverse event | 1 | 0 | 0 |
| Withdrew: Subject/guardian decision | 1 | 0 | 1 |
| Withdrew: Death | 4 | 4 | 4 |
| Withdrew: Withdrawal of consent | 1 | 1 | 0 |
To achieve this outcome, patients must fulfill all the following criteria, 1) survival, 2) no intervention with a second modality for ROP, 3) absence of active ROP and 4) absence of unfavorable structural outcome. Retinopathy of prematurity (ROP) is a pathologic process that occurs in the incompletely vascularized, developing retina of low birth-weight preterm neonates.
| Percentage of Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24 | 80.0 | 75.0 | 66.2 |
Intervention for ROP in either eye at or before the 24-week assessment visit with a treatment modality other than the modality of the first study treatment. Only descriptive analysis done.
| Percentage of participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Percentage of Participants Requiring Interventions With a Second Modality for ROP at Week 24 | 14.9 | 16.9 | 24.3 |
An event was defined as death, treatment switch, or the first occurrence of unfavorable structural outcomes in either eye. Only descriptive analysis done.
| Participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Number of Participants Experiencing an Event, From the First Study Treatment to the Last Study Visit | 14 | 18 | 23 |
Recurrence of ROP is defined as subjects receiving any post-baseline intervention in either eye at or before 24 weeks (ranibizumab re-treatment or switch to laser in the ranibizumab groups, switch to ranibizumab treatment in the laser group). Zone I consists of a circle, the radius of which extends from the center of the optic disc to twice the distance from the center of the optic disc to the center of the macula. Zone II extends centrifugally from the edge of zone I to the nasal ora serrata. Only descriptive analysis done.
| Percentage of participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| All participants | 31.1 | 31.2 | 18.9 |
| ZONE I | 35.7 | 53.3 | 28.6 |
| ZONE II | 28.3 | 17.4 | 13.0 |
Percent of Participants with Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.
| Percent of participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Mild | 23.3 | 32.9 | 17.4 |
| Moderate | 4.1 | 6.6 | 13.0 |
| Severe | 2.7 | 1.3 | 2.9 |
Blood samples for the determination of ranibizumab concentrations were collected in the Ranibizumab treatment arms only at the following time points: within 24 hours after the first administration of ranibizumab, at Day 15 and at Day 29. Only descriptive analysis done.
| picogram/milliliter (pg/mL) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg |
|---|---|---|
| Day 1 (Baseline) | 24700.0 ± 52400.00 | 12100.0 ± 25500.0 |
| Day 15 | 5830.0 ± 4750.0 | 27700.0 ± 144000 |
| Day 29 | 1810.0 ± 2990.0 | 732.0 ± 535.0 |
Blood samples for the determination of systemic VEGF levels were collected at the following time points: before the first investigational treatment, at Day 15 and at Day 29. Only descriptive analysis done.
| picogram/milliliter (pg/mL) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Day 1 | 239.0 ± 226.0 | 230.0 ± 224.0 | 232.0 ± 240.0 |
| Day 1 / no treatment modality switch | 239.0 ± 226.0 | 239.0 ± 233.0 | 233.0 ± 245.0 |
| Day 15 | 466.0 ± 1500.0 | 118.0 ± 129.0 | 180.0 ± 214.0 |
| Day 15 / no treatment modality switch | 498.0 ± 1560.0 | 124.0 ± 134.0 | 177.0 ± 224.0 |
| Day 29 | 117.0 ± 84.0 | 176.0 ± 142.0 | 161.0 ± 132.0 |
| Day 29 / no treatment modality switch | 117.0 ± 84.0 | 139.0 ± 75.3 | 163.0 ± 138.0 |
Patients randomized to receive Ranibizumab 0.1 mg or 0.2 mg received a single dose of intravitreal Ranibizumab to each eye on Day 1 (Baseline). Only descriptive analysis done.
| Injections | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Total Number of Ranibizumab Injections Received at Week 24 | 73 | 76 | 13 |
Percent of Participants with Non-Ocular Adverse Events regardless of Study Treatment and Procedure Relationship by Primary System Organ (SOCs) reported categorically (Mild, Moderate, Severe) 24 weeks after the first study treatment. Only descriptive analysis done.
| Percent of participants | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Mild | 37.0 | 27.6 | 31.9 |
| Moderate | 24.7 | 34.2 | 27.5 |
| Severe | 23.3 | 19.7 | 17.4 |
Body Length, Head Circumference and Knee to Heel Length were assessed. Only descriptive analysis done.
| centimeter (cm) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Day 85 / Body Length | 10.1 ± 2.59 | 11.0 ± 3.33 | 11.1 ± 3.65 |
| Day 169 / Body Length | 18.7 ± 3.28 | 18.6 ± 3.66 | 19.0 ± 4.50 |
| Day 85 / Head Circumference | 6.9 ± 1.96 | 6.5 ± 2.31 | 7.2 ± 2.13 |
| Day 169 / Head Circumference | 10.4 ± 2.12 | 10.3 ± 2.56 | 10.6 ± 2.61 |
| Day 85 / Knee to Heel Length | 2.9 ± 1.90 | 3.1 ± 1.65 | 3.1 ± 2.02 |
| Day 169 / Knee to Heel Length | 5.4 ± 2.86 | 5.1 ± 2.19 | 5.3 ± 2.15 |
Body weight was measured. Only descriptive analysis done.
| gram (g) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Day 85 / Weight | 2198.9 ± 615.68 | 2149.9 ± 754.27 | 2182.7 ± 612.70 |
| Day 169 / Weight | 3794.3 ± 782.48 | 3716.7 ± 897.15 | 3826.0 ± 882.17 |
Blood Pressure measurements were not required by the protocol. Instead, the most recent Systolic and Diastolic Blood Pressure expressed in millimeters of mercury (mmHg) measured as part of the routine clinical care were used. Only descriptive analysis done.
| millimeters of mercury (mmHg) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy |
|---|---|---|---|
| Day 85 / Sitting Diastolic Blood Pressure | 8.1 ± 14.66 | 7.0 ± 14.25 | 9.8 ± 16.95 |
| Day 85 / Sitting Systolic Blood Pressure | 6.3 ± 15.85 | 9.4 ± 15.73 | 15.5 ± 16.85 |
| Day 169 / Sitting Diastolic Blood Pressure | 11.5 ± 15.60 | 11.8 ± 14.42 | 14.7 ± 17.05 |
| Day 169 / Sitting Systolic Blood Pressure | 10.2 ± 16.15 | 11.2 ± 13.45 | 17.7 ± 19.35 |
Collected over Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit).. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.2 mg | 4/73 (5.5%) | 26/73 (35.6%) | 43/73 (58.9%) |
| Ranibizumab 0.1 mg | 4/76 (5.3%) | 24/76 (31.6%) | 47/76 (61.8%) |
| Laser | 4/69 (5.8%) | 24/69 (34.8%) | 37/69 (53.6%) |
| Event | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser |
|---|---|---|---|
| PneumoniaInfections and infestations | 4/73 | 0/76 | 2/69 |
| BronchiolitisInfections and infestations | 2/73 | 4/76 | 0/69 |
| Retinopathy of prematurityEye disorders | 2/73 | 1/76 | 3/69 |
| Necrotising colitisGastrointestinal disorders | 0/73 | 3/76 | 0/69 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/73 | 3/76 | 1/69 |
| VomitingGastrointestinal disorders | 0/73 | 1/76 | 2/69 |
| SepsisInfections and infestations | 0/73 | 1/76 | 2/69 |
| Perinatal brain damagePregnancy, puerperium and perinatal conditions | 0/73 | 0/76 | 2/69 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/73 | 2/76 | 2/69 |
| Bronchopulmonary dysplasiaRespiratory, thoracic and mediastinal disorders | 2/73 | 2/76 | 2/69 |
| Event | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser |
|---|---|---|---|
| Retinal haemorrhageEye disorders | 6/73 | 10/76 | 7/69 |
| PyrexiaGeneral disorders | 9/73 | 6/76 | 4/69 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 8/73 | 6/76 | 4/69 |
| AnaemiaBlood and lymphatic system disorders | 4/73 | 8/76 | 5/69 |
| NasopharyngitisInfections and infestations | 7/73 | 5/76 | 4/69 |
| PneumoniaInfections and infestations | 1/73 | 1/76 | 6/69 |
| Conjunctival haemorrhageEye disorders | 6/73 | 6/76 | 2/69 |
| Upper respiratory tract infectionInfections and infestations | 6/73 | 3/76 | 1/69 |
| ConjunctivitisInfections and infestations | 1/73 | 6/76 | 2/69 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 5/73 | 5/76 | 4/69 |
| Age, Continuous(Weeks) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| Mean | 25.8 ± 2.25 | 26.5 ± 2.57 | 26.2 ± 2.59 | 26.1 ± 2.48 |
| Sex: Female, Male(Participants) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| Female | 41 | 40 | 37 | 118 |
| Male | 33 | 37 | 37 | 107 |
| Race (NIH/OMB)(Participants) | Ranibizumab 0.2 mg | Ranibizumab 0.1 mg | Laser Therapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 27 | 22 | 23 | 72 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 4 | 3 | 7 |
| White | 43 | 45 | 45 | 133 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 6 | 3 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Dec 2015 to primary completion in Dec 2017, 23 months.
Results were first posted in Jul 2018, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab